Symptoms are otherwise relatively non-specific and may be related to the disease site, e.g., neurologic compromise in the event of invasion into a nerve plexus or mass-effect due to tumor size/location [2]
The FDA explains that GLP-1 receptor agonists mimic the effects of a natural hormone released by the intestine, help lower blood sugar after eating, and act on brain regions involved in appetite and food intake
We are aware that several compounding pharmacies, weight loss clinics, and medical spas are purporting to sell or offer unapproved compounded semaglutide products both in Canada and the U.S., a spokesperson for Novo Nordisk Canada said in an emailed statement in July 2024
Potentially slower effects: Injections release the full dose quickly
Scenarios with investigational treatments discontinued prior to treatment intensification to basal + bolus insulin estimate ICERs approximately 10% lower (i.e., more favourable to semaglutide)